As opioid overdose deaths climb, legislation supporting pharmacists in developing their role to address the crisis has expanded. Although Minnesota pharmacists are encouraged to utilize opiate antagonist, syringe access and authorized collector legislation, the use patterns of these tools are unknown.
Methods:
A mixed-methods approach was used to survey 8405 Minnesota-licensed pharmacists on their practices related to the opioid crisis. An analysis of community pharmacist utilization of opioid-related legislation was conducted.
Results:
The majority (88.64%) of respondents indicated that they had not dispensed naloxone in the past month using a protocol; 59.69% reported that they had not dispensed naloxone by any method in the past month. Over sixty percent (60.61%) of respondents agreed they are comfortable with dispensing syringes and would dispense noninsulin syringes in their pharmacy under the statewide Syringe Access Initiative; 25.86% reported that they are not comfortable dispensing syringes. The majority (78.64%) of respondents reported that they do not participate in collecting unwanted pharmaceuticals.
Conclusion:
While pharmacists have the potential to play a key role in efforts focused on addressing the opioid crisis through harm reduction strategies, this role and the use of supporting legislation is currently underutilized in the state of Minnesota.
RuddRASethPDavidF, et al.Increases in drug and opioid-involved overdose deaths—United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(50-51):1445–1452.
2.
Centers for Disease Control and Prevention. CDC WONDER. 2018. Accessed March 28, 2019. https://wonder.cdc.gov/
BouillonTBruhnJRoepckeH, et al.Opioid-induced respiratory depression is associated with increased tidal volume variability. Eur J Anaesthesiol. 2003;20(2):127–133.
5.
PattinsonKT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–758. doi: 10.1093/bja/aen094.
6.
MichielsC. Physiological and pathological responses to hypoxia. Am J Pathol. 2004;164(6):1875–1882. Accessed March 28, 2019.
7.
DavisCWebbDBurrisS. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics. 2013;41(suppl 1):33–36. doi: 10.1111/jlme.12035.
8.
LewanowitschTIrvineRJ. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal. Eur J Pharmacol. 2002;445(1-2):61–67.
9.
ChamberlainJMKleinBL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med. 1994;12(6):650–660. doi: 10.1016/j.neuropharm.2017.10.016.
BakhirevaLNBautistaACanoS, et al.Barriers and facilitators to dispensing of intranasal naloxone by pharmacists. Subst Abus. 2018; 39(3):331–341. doi: 10.1080/08897077.2017.1391924.
15.
FreemanPRGoodinATroskeS, et al.Pharmacists’ role in opioid overdose: Kentucky pharmacists’ willingness to participate in naloxone dispensing. J Am Pharm Assoc (2003). 2017;57(2S):S28–S33. doi: 10.1016/j.japh.2016.12.064.
16.
GreenTCCasePFiskeH, et al.Perpetuating stigma or reducing risk? Perspective from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc (2003). 2017;57(2S):S19–S27. doi: 10.1016/j.japh.2017.01.013.
17.
ThorntonJDLyversEScottVGG, et al.Pharmacists’ readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc (2003). 2017;57(2S):S12–S18. doi: 10.1016/j.japh.2016.12.070.
18.
HagemeierNETudiverFBrewsterS, et al.Prescription drug abuse communication: a qualitative analysis of prescriber and pharmacist perceptions and behaviors. Res Social Adm Pharm. 2016;12(6):937–948. doi: 10.1016/j.sapharm.2015.12.008.
19.
WuLTGhitzaUEBurnsAL, et al.The opioid overdose epidemic: opportunities for pharmacists. Subst Abuse Rehabil. 2017;8:53–55. doi: 10.2147/SAR.S144268.
20.
MaxwellSBiggDStanczykiewiczK, et al.Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25(3):89–96. doi: 10.1300/J069V25n03_11.
21.
SealKHThawleyRGeeL, et al.Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303–311. doi: 10.1093/jurban/jti053.
22.
WagnerKDValenteTWCasanovaM, et al.Evaluation of an overdose prevention and response training programme for injection drug users in the skid row area of Los Angeles, California. Int J Drug Policy. 2010;21(3):186–193. doi: 10.1016.j.drugpo.2009.01.003.
23.
KerenskyTWalleyAY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12(1):4. doi:10.1186/s13722-016-0068-3.
24.
CoffinPOBeharERoweC, et al.Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245–252. doi: 10.7326/M15-2771.
25.
DoleacJLMukherjeeA. The moral hazard of lifesaving innovations: naloxone access, opioid abuse, and crime. SSRN Electronic Journal. Discussion Paper 11489. 2018. doi: 10.2139/ssrn.3135264.
FlemingMLBapatSSVariscoTJ. Using the theory of planned behavior to investigate community pharmacists’ beliefs regarding engaging patients about prescription drug misuse [published online ahead of print October 28, 2018]. Res Social Adm Pharm. 2018;pii:S1551-7411(18)30290-0. doi: 10.1016/j.sapharm.2018.10.027
28.
AdamsAJDesselleSPMcKeirnanKC. Pharmacy technician-administered vaccines: on perceptions and practice reality. Pharmacy (Basel). 2018;6(4):124. doi: 10.3390/pharmacy6040124.
29.
GeorgeDLSmithMJDraugalisJR, et al.Community pharmacists’ beliefs regarding improvement of star ratings scores using the theory of planned behavior. J Am Pharm Assoc (2003). 2018;58(1):21–29. doi:10.1016/j.japh.2017.09.001.
30.
RichJDAdashiEY. Ideological anachronism involving needle and syringe exchange programs: lessons from the Indiana HIV outbreak. JAMA. 2015;314(1):23–24. doi: 10.1001/jama.2015.6303.
31.
VlahovDJungeB. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998;113(suppl 1):75–80.
32.
BakerA. The ongoing battle for syringe exchange. J AIDS HIV Infec. 2016;2(1):101. doi: 10.15744/2454-499X.2.101.
KinrysGGoldAKWorthingtonJJ, et al.Medication disposal practices: increasing patient and clinician education on safe methods. J Int Med Res. 2018;46(3):927–939. doi: 10.1177/0300060517738681.
35.
SasuSKümmererKKranertM. Assessment of pharmaceutical waste management at selected hospitals and homes in Ghana. Waste Manag Res. 2012;30(6):625–630. doi: 10.1177/0734242X11423286.
36.
SeehusenDAEdwardsJ. Patient practices and beliefs concerning the disposal of medications. J Am Board Fam Med. 2006;19(6):542–547. doi: 10.3122/jabfm.19.6.542.
37.
WulzJLSungHDuganBD, et al.The pharmacist role in the development and implementation of a naloxone prescription program in Alabama. J Am Pharm Assoc (2003). 2017;57(2S):S141–S147. doi: 10.1016/j.sapharm.2015.12.008.
38.
CarpenterDMRobertsCAWestrickSC, et al.A content review of online naloxone continuing education courses for pharmacists in states with standing orders. Res Social Adm Pharm. 2018;14(10):968–978. doi: 10.1016/j.sapharm.2017.11.011.
39.
JacobsonANBratbergJPMonkM, et al.Retention of student pharmacists’ knowledge and skills regarding overdose management with naloxone. Subst Abuse. 2018;12:1–6. doi: 10.1080/08897077.2018.1439797.
40.
MaguireMAPavlakosRNMehtaBH, et al.A naloxone and harm reduction educational program across four years of a doctor of pharmacy program. Curr Pharm Teach Learn. 2018;10(1):72–77. doi: 10.1016/j.cptl.2017.09.007.
41.
BaileyAMWermelingDP. Naloxone for opioid overdose prevention: pharmacists’ role in community-based practice settings. Ann Pharmacother. 2014;48(5):601–606. doi: 10.1177/1060028014523730.
42.
CochranGHruschakVDeFosseB, et al.Prescription opioid abuse: pharmacists’ perspective and response. Integr Pharm Res Pract. 2016;5:65–73. doi: 10.2147/IPRP.S99539.
43.
ComptonWMJonesCMSteinJB, et al.Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Social Adm Pharm. 2019;15(8):910–916.
